Pharmacokinetics of Piperacillin/Tazobactam in Patients Treated by Continuous Renal Replacement Therapy

• Status: Completed
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The pharmacokinetics of piperacillin/tazobactam will be evaluated in twenty septic patients with renal failure undergoing continuous veno-venous hemodiafiltration.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Toulouse
• Treatments: Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam

Criteria

Inclusion Criteria:

• 18 years of age and older .

• Females of childbearing potential must have a negative pregnancy test at screening.

• Subjects whose life expectancy is estimated over 7 days.

• Anuric patients requiring continuous venovenous hemodiafiltration

• Septic patients,severe sepsis or septic shock

• Written informed consent should be given either by the patient or a member of his family

Exclusion Criteria:

• Subjects with a history of true allergy or adverse drug reactions

• Pathogens whose antibiotic susceptibility is not proved.

• Patients having impaired hepatic function

• Contraindication of anticoagulation by heparin

• Residual renal function

• Participation in a clinical trial

• Interruption of treatment by piper/tazo or hemodiafiltration during the study.

• Patients with psychiatric disorder or serious medical condition which in the opinion of the investigator may lead to complexity in patient management.